Anteris Technologies Global Corp. — Capital/Financing Update 2023

Jun 12, 2023

ASX ANNOUNCEMENT

13 June 2023

Latest patient group show best results to date at 30 days

BRISBANE, Australia and MINNEAPOLIS, USA , Anteris Technologies Ltd (Anteris or the Company) (ASX: AVR) recently presented new patient data at the TVT conference. The results show DurAVR™ THV maintained excellent haemodynamic performance at 30 days, as previously reported with this patient cohort at 48 hours post-procedure.

Preliminary Results:

• Results comprised the latest 7 patients enrolled in the DurAVR™ First-In-Human Study; 100% implant success was achieved with no device-related complications.

• Study participants’ baseline characteristics: mean age 74.86 years, gender 86% female, mean annulus diameter 22.33 mm, New York Heart Class II and III - 71% and 29%, respectively (classifying the extent of heart failure).

• 30-day results are consistent with data previously reported at 48 hours post-procedure. EOAs saw a 168% increase from 0.76 cm[2] at baseline to 2.04 cm[2] at 30 days, while MPG decreased by 87% from 56.86 mmHg to 7.53 mmHg.

Anteris Technologies Chief Executive Officer Wayne Paterson said :

“The results from the latest seven patients signal that DurAVR™ THV continues to perform well in small annulus sizes. We saw greater haemodynamic improvement in these difficult-to-treat patients, and this encouraging data continues to support the thesis that DurAVR™ THV, a new class of biomimetic valve, will be an important treatment option for patients in the future.”

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

Its focus is developing next-generation technologies that help healthcare professionals deliver consistent life-changing outcomes for patients.

Anteris’ DurAVR[TM] 3D single-piece aortic heart valve replacement addresses the needs of today’s younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient’s lifetime.

Anteris Technologies Ltd Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066 Customer Service

T +61 1300 550 310 | F +61 1300 972 437 | E info.au@anteristech.com | W anteristech.com

==> picture [95 x 51] intentionally omitted <==

Brisbane ▪ Minneapolis ▪ Geneva ▪ Malaga

The proven benefits of its patented ADAPT[®] tissue technology, paired with the unique design of our DurAVR[TM] 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.

Authorisation and Additional information

This announcement was authorised by the Board of Directors.

For more information:

Investor contact

Deanne Curry GRACosway E: investors@anteristech.com M: +61 414 388 997

Media contact

Nick Howe GRACosway E: nhowe@gracosway.com.au M: +61 407 183 221

www.anteristech.com

Twitter: @AnterisTech

Facebook: www.facebook.com/AnterisTech

LinkedIn: https://www.linkedin.com/company/anteristech

==> picture [95 x 52] intentionally omitted <==